Bristol-Myers Squibb Company (BMY) to Capitalize on Cell Therapy Edge to Pursue CAR-T Treatment Opportunities

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best conservative stocks to buy now. On September 23, at the Bernstein Insights: Healthcare Leaders and Disruptors, the company emphasized its leadership in cell therapy.

The remarks come on the company treating 13,000 patients with cell therapy while leveraging extensive clinical data. Likewise, it is currently working on Orva-cel and Breyanzi, which it believes pose significant prospects in targeting autoimmune and neuroinflammatory diseases.

“As we sit four years later, after treating 13,000 patients, we sit in a unique position at Bristol Myers Squibb where we have more manufactured clinical and translational data than almost anyone else in this space. It has afforded us the opportunity not only to grow our inline assets, but it’s helped us accelerate our pipeline,” said Lynelle, Head of the Cell Therapy business, Bristol Myers Squibb.

Approved to treat certain adult lymphomas, Breyanzi is the company’s lead cell-based gene therapy. With only 20% of eligible patents currently receiving CAR T therapy, the company is staring at tremendous opportunities.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and sells innovative medicines to treat serious diseases, with a focus on areas like oncology, immunology, hematology, and cardiovascular disease.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Performing Penny Stocks to Buy Now and 11 Best Healthcare Penny Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.